This playbook explores how an analytical-first strategy can help biosimilar developers reduce risk, streamline development and speed market entry. Recent FDA and EMA changes are reshaping the path to market for biosimilars, putting greater emphasis on analytical characterization. For developers pursuing a share of the growing biosimilar opportunity, a strong comparative analytical assessment (CAA) can help reduce regulatory risk and keep programs moving. This playbook examines what an analytical-first strategy looks like and how developers can evaluate their analytical partner, from method breadth and CQA coverage to formulation expertise and regulatory inspection history. Readers will learn how to: Understand the key elements of a robust CAA Identify potential analytical bottlenecks and partner gaps Explore how standalone, centralized analytics can support faster, more flexible development
